Products
Ibalizumab was approved in the United States in 2018 and in the EU in 2019 (Trogarzo, TaiMed Biologics).
Structure and properties
Ibalizumab is a humanized IgG4 monoclonal antibody. It is produced by biotechnological methods. Unlike most antiviral agents, it is directed against an endogenous drug target rather than the virus.
Effects
Ibalizumab has antiviral properties. The antibody binds to the CD4 receptor on the surface of host cells. The glycoprotein gp120 of HIV also interacts with this receptor. Ibalizumab does not inhibit the interaction between CD4 and gp120, but it prevents the subsequent interaction with the coreceptors CCR5 or CXCR4. Through this mechanism, there is no immunosuppression. Thus, the virus has its hand on the door latch but cannot open the door.
Indications
For the treatment of refractory HIV infection.
Dosage
According to the SmPC. The drug is administered intravenously every two weeks.
Contraindications
For complete precautions, see the drug label.
Adverse effects
The most common possible adverse effects include diarrhea, dizziness, nausea, and skin rashes.
